Non-childbearing potential (ie, post-menopausal for at least 1 year or surgically sterile)
You may not be if
History of laboratory-confirmed RSV and/or laboratory-confirmed HMPV infection affecting the participant and/or the participant's household in the previous 12 months
Previous history of myocarditis, pericarditis, and/or myopericarditis
Screening electrocardiogram (ECG) that is consistent with possible myocarditis, pericarditis, and/or myopericarditis or, in the opinion of the investigator, demonstrates clinically relevant abnormalities that may affect participant safety or study results
Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
Previous history of Guillain-Barré Syndrome
Any vaccine given 4 weeks before or 4 weeks after study intervention
Previous vaccination against RSV and/or HMPV with an investigational or marketed vaccine
Receipt of any mRNA vaccine/product in the 2 months preceding study intervention administration
Has received a blood transfusion or blood-derived products, including immunoglobulins, in the past 3 months
Any screening laboratory parameter with laboratory abnormality \> Grade 1 or deemed clinically significant by the investigator; if deemed appropriate, investigator may repeat these assessments
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
